Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633497 | 0.83 | NPC1 (0.55) | HDAC6HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL990856 | 0.81 | HCAR3 (0.65) | HDAC6HDAC1GRM5 | |
| SCHEMBL3630022 | 0.81 | RAB9A (0.56) | HDAC6HDAC1HDAC3HDAC2NPC1 | |
| SCHEMBL990937 | 0.79 | GRM5 (0.54) | HDAC6HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2497628 | 0.79 | HDAC6 (0.55) | HDAC6HDAC1HDAC3HDAC2NPC1 | |
| SCHEMBL30923165 | 0.79 | HDAC6 (0.55) | HDAC6HDAC1HDAC3HDAC2NPC1 | |
| SCHEMBL670354 | 0.78 | HDAC6 (0.72) | HDAC6HDAC1HDAC3HDAC2CSNK2A1 | |
| SCHEMBL3628259 | 0.77 | GRM5 (0.67) | GRM5 | |
| SCHEMBL3635773 | 0.77 | P4HTM (0.55) | NPC1RAB9ASMN1; SMN2SORT1 | |
| SCHEMBL181465 | 0.77 | HDAC1 (0.62) | HDAC6HDAC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679299-A | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | HDAC6 106/4885HDAC1 125/4885HDAC3 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.